000170420 001__ 170420
000170420 005__ 20260420103355.0
000170420 0247_ $$2doi$$a10.1111/nyas.70255
000170420 0248_ $$2sideral$$a148888
000170420 037__ $$aART-2026-148888
000170420 041__ $$aeng
000170420 100__ $$0(orcid)0000-0003-4726-7821$$aJiménez-Alesanco, Ana$$uUniversidad de Zaragoza
000170420 245__ $$aRepurposing Drugs as Bacteroides fragilis BFT-3 Inhibitors in the Animal Infection Model Galleria mellonella
000170420 260__ $$c2026
000170420 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170420 5203_ $$aBacteroides fragilis is a key component of the human gut microbiota, although enterotoxigenic strains (ETBF), which produce B. fragilis toxin (BFT), can act as opportunistic pathogens. BFT disrupts intestinal epithelial integrity and contributes to conditions such as inflammatory bowel disease and colorectal cancer. This study aimed to characterize three allosteric inhibitors of BFT-3 (isoform 3 of BFT), previously identified by our group through high-throughput screening of US Food and Drug Administration approved drugs. We evaluated their activities in vitro and in vivo. Using Galleria mellonella larvae as a novel infection model for B. fragilis, we assessed the antimicrobial and antivirulence potential of these compounds. Among the three tested compounds, MOA4 demonstrated superior efficacy, enhanced bacterial clearance in vivo, and increased larval survival in a dose-dependent manner, with minimal toxicity. Synergy studies have revealed the potential combinatory effects of MOA4 and conventional antibiotics. These findings establish G. mellonella as a valuable alternative model for studying B. fragilis infections and highlight MOA4 as a promising candidate to be repurposed for the treatment of B. fragilis-mediated diseases while preserving commensal microbiota.
000170420 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2021-127296OB-I00$$9info:eu-repo/grantAgreement/ES/DGA/B08-24R$$9info:eu-repo/grantAgreement/ES/DGA/B25-23R$$9info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI18-00349$$9info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661$$9info:eu-repo/grantAgreement/ES/ISCIII/PI21-00394$$9info:eu-repo/grantAgreement/ES/MCIU/PID2024-160408OB-I00$$9info:eu-repo/grantAgreement/ES/MICINN-AEI/PRTR-C17.I1$$9info:eu-repo/grantAgreement/ES/MINECO/BFU2016-78232-P
000170420 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000170420 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170420 700__ $$aGómara-Lomero, Marta
000170420 700__ $$aJeblaoui, Hajar
000170420 700__ $$0(orcid)0000-0002-1232-6310$$aVega, Sonia$$uUniversidad de Zaragoza
000170420 700__ $$0(orcid)0000-0001-5702-4538$$aVelázquez-Campoy, Adrián$$uUniversidad de Zaragoza
000170420 700__ $$0(orcid)0000-0003-2076-844X$$aAínsa, José Antonio$$uUniversidad de Zaragoza
000170420 700__ $$0(orcid)0000-0001-5664-1729$$aAbián, Olga$$uUniversidad de Zaragoza
000170420 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000170420 7102_ $$10$$2X$$aUniversidad de Zaragoza$$bInstitutos Univ. de Investig.$$cÁrea RPT Laboral BIFI
000170420 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000170420 773__ $$g1557, 1 (2026), 16$$pAnn. N.Y. Acad. Sci.$$tANNALS OF THE NEW YORK ACADEMY OF SCIENCES$$x0077-8923
000170420 8564_ $$s1867841$$uhttps://zaguan.unizar.es/record/170420/files/texto_completo.pdf$$yVersión publicada
000170420 8564_ $$s2503900$$uhttps://zaguan.unizar.es/record/170420/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170420 909CO $$ooai:zaguan.unizar.es:170420$$particulos$$pdriver
000170420 951__ $$a2026-04-18-10:49:14
000170420 980__ $$aARTICLE